Adverum Biotechnologies Inc. (ADVM), a clinical-stage company pioneering the use of gene therapy for ocular diseases, has a key clinical trial catalyst to watch in the coming months involving its potential One And Done therapy for wet AMD, Ixo-vec.
Ixo-vec is an adeno-associated virus (AAV) gene therapy that utilizes the AAV.7m8 capsid for intravitreal delivery (IVT) to transduce retinal tissue and produce sustained intraocular aflibercept for long-term wet AMD management and preservation of vision.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com